Advancing islet transplantation: From engraftment to the immune response

R. F. Gibly, J. G. Graham, X. Luo, W. L. Lowe, B. J. Hering, L. D. Shea*

*Corresponding author for this work

Research output: Contribution to journalReview article

70 Citations (Scopus)

Abstract

The promise and progress of islet transplantation for treating type 1 diabetes has been challenged by obstacles to patient accessibility and long-term graft function that may be overcome by integrating emerging technologies in biomaterials, drug delivery and immunomodulation. The hepatic microenvironment and traditional systemic immunosuppression stress the vulnerable islets and contribute to the limited success of transplantation. Locally delivering extracellular matrix proteins and trophic factors can enhance transplantation at extrahepatic sites by promoting islet engraftment, revascularisation and long-term function while avoiding unintended systemic effects. Cell- and cytokine-based therapies for immune cell recruitment and reprogramming can inhibit local and systemic immune system activation that normally attacks transplanted islets. Combined with antigen-specific immunotherapies, states of operational tolerance may be achievable, reducing or eliminating the long-term pharmaceutical burden. Integration of these technologies to enhance engraftment and combat rejection may help to advance the therapeutic efficacy and availability of islet transplantation.

Original languageEnglish (US)
Pages (from-to)2494-2505
Number of pages12
JournalDiabetologia
Volume54
Issue number10
DOIs
StatePublished - Oct 1 2011

Fingerprint

Islets of Langerhans Transplantation
Transplantation
Technology
Immunomodulation
Extracellular Matrix Proteins
Biocompatible Materials
Type 1 Diabetes Mellitus
Pharmaceutical Preparations
Immunotherapy
Immunosuppression
Immune System
Cytokines
Transplants
Antigens
Liver
Therapeutics
Cellular Reprogramming

Keywords

  • Biomaterial
  • Biotechnology
  • Diabetes
  • Extrahepatic
  • Immunomodulation
  • Islet transplantation
  • Review
  • Scaffold
  • Tissue engineering
  • Tolerance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Gibly, R. F. ; Graham, J. G. ; Luo, X. ; Lowe, W. L. ; Hering, B. J. ; Shea, L. D. / Advancing islet transplantation : From engraftment to the immune response. In: Diabetologia. 2011 ; Vol. 54, No. 10. pp. 2494-2505.
@article{ed02588cfd3e4f31a13fd38784d216dd,
title = "Advancing islet transplantation: From engraftment to the immune response",
abstract = "The promise and progress of islet transplantation for treating type 1 diabetes has been challenged by obstacles to patient accessibility and long-term graft function that may be overcome by integrating emerging technologies in biomaterials, drug delivery and immunomodulation. The hepatic microenvironment and traditional systemic immunosuppression stress the vulnerable islets and contribute to the limited success of transplantation. Locally delivering extracellular matrix proteins and trophic factors can enhance transplantation at extrahepatic sites by promoting islet engraftment, revascularisation and long-term function while avoiding unintended systemic effects. Cell- and cytokine-based therapies for immune cell recruitment and reprogramming can inhibit local and systemic immune system activation that normally attacks transplanted islets. Combined with antigen-specific immunotherapies, states of operational tolerance may be achievable, reducing or eliminating the long-term pharmaceutical burden. Integration of these technologies to enhance engraftment and combat rejection may help to advance the therapeutic efficacy and availability of islet transplantation.",
keywords = "Biomaterial, Biotechnology, Diabetes, Extrahepatic, Immunomodulation, Islet transplantation, Review, Scaffold, Tissue engineering, Tolerance",
author = "Gibly, {R. F.} and Graham, {J. G.} and X. Luo and Lowe, {W. L.} and Hering, {B. J.} and Shea, {L. D.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s00125-011-2243-0",
language = "English (US)",
volume = "54",
pages = "2494--2505",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "10",

}

Advancing islet transplantation : From engraftment to the immune response. / Gibly, R. F.; Graham, J. G.; Luo, X.; Lowe, W. L.; Hering, B. J.; Shea, L. D.

In: Diabetologia, Vol. 54, No. 10, 01.10.2011, p. 2494-2505.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advancing islet transplantation

T2 - From engraftment to the immune response

AU - Gibly, R. F.

AU - Graham, J. G.

AU - Luo, X.

AU - Lowe, W. L.

AU - Hering, B. J.

AU - Shea, L. D.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The promise and progress of islet transplantation for treating type 1 diabetes has been challenged by obstacles to patient accessibility and long-term graft function that may be overcome by integrating emerging technologies in biomaterials, drug delivery and immunomodulation. The hepatic microenvironment and traditional systemic immunosuppression stress the vulnerable islets and contribute to the limited success of transplantation. Locally delivering extracellular matrix proteins and trophic factors can enhance transplantation at extrahepatic sites by promoting islet engraftment, revascularisation and long-term function while avoiding unintended systemic effects. Cell- and cytokine-based therapies for immune cell recruitment and reprogramming can inhibit local and systemic immune system activation that normally attacks transplanted islets. Combined with antigen-specific immunotherapies, states of operational tolerance may be achievable, reducing or eliminating the long-term pharmaceutical burden. Integration of these technologies to enhance engraftment and combat rejection may help to advance the therapeutic efficacy and availability of islet transplantation.

AB - The promise and progress of islet transplantation for treating type 1 diabetes has been challenged by obstacles to patient accessibility and long-term graft function that may be overcome by integrating emerging technologies in biomaterials, drug delivery and immunomodulation. The hepatic microenvironment and traditional systemic immunosuppression stress the vulnerable islets and contribute to the limited success of transplantation. Locally delivering extracellular matrix proteins and trophic factors can enhance transplantation at extrahepatic sites by promoting islet engraftment, revascularisation and long-term function while avoiding unintended systemic effects. Cell- and cytokine-based therapies for immune cell recruitment and reprogramming can inhibit local and systemic immune system activation that normally attacks transplanted islets. Combined with antigen-specific immunotherapies, states of operational tolerance may be achievable, reducing or eliminating the long-term pharmaceutical burden. Integration of these technologies to enhance engraftment and combat rejection may help to advance the therapeutic efficacy and availability of islet transplantation.

KW - Biomaterial

KW - Biotechnology

KW - Diabetes

KW - Extrahepatic

KW - Immunomodulation

KW - Islet transplantation

KW - Review

KW - Scaffold

KW - Tissue engineering

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=80054102624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054102624&partnerID=8YFLogxK

U2 - 10.1007/s00125-011-2243-0

DO - 10.1007/s00125-011-2243-0

M3 - Review article

C2 - 21830149

AN - SCOPUS:80054102624

VL - 54

SP - 2494

EP - 2505

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 10

ER -